Director/PDMR Shareholding

RNS Number : 9965J

Provexis PLC

15 September 2016

 

15 September 2016

Provexis plc

Directors' Share Purchase

Further to its announcements on 9 June 2016, 29 June 2016 and 2 August 2016 and its preliminary results announcement on 7 September 2016, Provexis plc ('Provexis' or the 'Company'), announces that it has raised £25,000 via a placing (the 'Placing'), conditional on admission to trading on AIM, of 10,416,667 new ordinary shares of 0.1p each at 0.24p per share (the 'New Provexis Shares') with the Company's Chairman Dawson Buck.

On 9 June 2016 the Company announced that it had non-legally binding indications of interest in a subscription to raise approximately £160,000 at a subscription price of 0.24 pence per ordinary share.

On 29 June 2016 the Company announced that it had a non-legally binding indication of a £25,000 interest in a subscription to 10,416,667 new ordinary shares of 0.1p each at 0.24p per share from Dawson Buck, with indications of a £160,000 interest at 0.24p per share from other investors.

On 2 August 2016, under the Company's code on dealings in securities, it was announced that the Company was in a close period for directors' dealings which meant that Dawson Buck would not be able to take up his subscription until the Company's audited annual report and accounts were published. Dawson Buck therefore gave a stated intention on 2 August to subscribe to 10,416,667 shares at a subscription price of 0.24p totalling £25,000, with his formal commitment to and payment for the subscription to take effect in September immediately after publication of the Company's annual report and accounts.

On 2 August 2016 the Company also announced that it had raised £224,000 via a placing of 93,333,340 new ordinary shares of 0.1p each at 0.24p per share with new and existing investors, which excluded Dawson Buck's stated intention to subscribe to 10,416,667 shares totalling £25,000.

The Company's annual report and accounts were distributed to shareholders on 7 September 2016, hence the announcement today confirming that Dawson Buck's stated intention to subscribe to 10,416,667 shares at 0.24p per share totalling £25,000 has been realised. The total funds raised from the placing with new and existing investors announced on 2 August 2016 and the placing with Dawson Buck announced today amount to £249,000 with no commissions or expenses payable. The funds raised will be used to provide the Company with additional working capital over the coming year, to include the working capital required to hold stock of the Company's Fruitflow® + Omega-3 dietary supplement product which was launched online at www.fruitflowplus.com on 29 June 2016.

The New Provexis Shares have been issued at 0.24p per share and rank pari passu in all respects with the existing ordinary shares of 0.1p each in Provexis.

The Placing represents a discount of 39.7 per cent to the closing mid-market price per Ordinary Share on 15 September 2016, being the latest practicable date prior to this announcement. The Placing represents a discount of 9.09 per cent to the closing mid-market price per Ordinary Share on 9 June 2016, being the date when a proposed subscription at 0.24p per share was first announced.

Following the purchase, Mr Buck is interested in 25,416,667 Ordinary Shares which amounts to approximately 1.45 per cent of the current issued share capital of the Company.

Application will be made to the London Stock Exchange for the 10,416,667 New Provexis Shares to be admitted to trading on AIM. It is expected that the admission will become effective and that trading in the New Provexis Shares will commence on 22 September 2016 ("Admission").

Following Admission, the Company's enlarged issued share capital will comprise 1,750,818,174 ordinary shares with voting rights. The Company does not hold any shares in treasury. This figure of 1,750,818,174 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information.

- ends -

For further information please contact:

Provexis plc                                                     Tel:      [phone]

Ian Ford, Finance Director                               [e-mail]

Cenkos Securities plc                                      Tel:      [phone]

Bobbie Hilliam

Notes for editors

About Provexis plc

AIM-listed Provexis is focused on the development and licensing of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.

In May 2009, the Company's Fruitflow® technology was the first to be substantiated by the European Food Safety Authority ("EFSA") under the new Article 13(5) for proprietary and emerging science. In December 2009 the European Commission authorised the health claim "Helps maintain normal platelet aggregation, which contributes to healthy blood flow", which was the first wording to be authorised under Article 13(5).

In June 2010 it was announced that the Company had entered into a long-term Alliance Agreement with DSM Nutritional Products to commercialise Fruitflow®, and in June 2015 the Company confirmed it had agreed significantly enhanced financial terms for its Alliance Agreement with DSM for Fruitflow®.

The Company's Alliance partner DSM Nutritional Products has developed the market actively for the Company's novel, patented Fruitflow® heart-health ingredient in all global markets, with over 50 regional consumer healthcare brands now having been launched by direct customers of DSM, and with a number of further regional brands having been launched through DSM's distributor channels.

An increasing number of further commercial projects have been initiated by DSM with prospective customers, including some prospective customers which are part of global businesses, with good prospects for these projects to be launched as consumer products. Interest in the technology exists in all major global markets.

On 29 June 2016 the Company launched a high quality dietary supplement product containing Fruitflow® and Omega-3 which is being sold initially from a separate, dedicated website www.fruitflowplus.com on a mail order basis.

The Company is planning to conduct a Key Opinion Leaders' roundtable event for Fruitflow® in London on 29 September 2016, focussed on raising awareness of the importance of blood flow in cardiovascular health, and the effectiveness of dietary antiplatelets. The roundtable will be attended by key scientists from Provexis and DSM, along with a number of interested health care professionals with close links to the media. It is anticipated that some UK national media will also attend the event. The event will be recorded with a view to producing two further promotional videos: a video for Fruitflow® targeting prospective trade customers, and a video for Fruitflow® + Omega-3 capsules targeting prospective consumers.

Video content recorded at the event and subsequently will be used to promote Fruitflow® and the Company's Fruitflow® + Omega-3 capsules more widely across key digital and other mainstream media channels.

The Company and DSM are keen to secure greater medical advocacy for Fruitflow® and the roundtable event forms part of this strategy. The roundtable event will also be supported by a broader consumer PR campaign.

The Company is engaged in a two stage collaboration agreement with the University of Oslo ('the University') to undertake further research into the relationship between Fruitflow® and blood pressure regulation. The Company is very pleased with the encouraging results from the first stage of the collaboration with strong evidence that a standard dose of Fruitflow® has the potential to give a clinically relevant reduction in systolic blood pressure. The Company and the University expect to be able to complete a small clinical trial by way of a proof of principle study in Q4 2016 and the results of the proof of principle study will be announced as soon as possible thereafter.

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

For further information, please visit www.provexis.com

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dawson Buck
2	Reason for the notification
a)	Position/status	Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Provexis plc
b)	LEI	N/a
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1p each ISIN: GB00B0923P27
b)	Nature of the transaction	Subscription for new shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 0.24p 10,416,667
d)	Aggregated information - Aggregated volume - Price	10,416,667 0.24p
e)	Date of the transaction	15 September 2016
f)	Place of the transaction	N/a

 

END

 

 

DSHGGUMUBUPQGQA